INT96619

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.36
First Reported 2001
Last Reported 2009
Negated 0
Speculated 0
Reported most in Abstract
Documents 7
Total Number 8
Disease Relevance 8.96
Pain Relevance 7.47

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

cytosol (CSAD) small molecule metabolic process (CSAD) lyase activity (CSAD)
cellular nitrogen compound metabolic process (CSAD)
Anatomy Link Frequency
trigeminal ganglion 2
CSAD (Homo sapiens)
Pain Link Frequency Relevance Heat
depression 66 100.00 Very High Very High Very High
nMDA receptor 1 99.68 Very High Very High Very High
Endep 10 99.62 Very High Very High Very High
anticonvulsant 1 99.28 Very High Very High Very High
Migraine 290 98.92 Very High Very High Very High
antagonist 9 98.48 Very High Very High Very High
Pain 33 96.36 Very High Very High Very High
trigeminal ganglion 6 95.64 Very High Very High Very High
central sensitization 6 95.44 Very High Very High Very High
Peripheral sensitization 3 91.84 High High
Disease Link Frequency Relevance Heat
Depression 66 100.00 Very High Very High Very High
Headache 374 98.92 Very High Very High Very High
Epilepsy 27 98.12 Very High Very High Very High
Pain 33 96.36 Very High Very High Very High
Ganglion Cysts 8 95.20 Very High Very High Very High
Migraine Without Aura 18 90.84 High High
Cluster Headache 3 87.68 High High
Infarction 1 67.68 Quite High
Brain Hemorrhage 1 67.24 Quite High
Brain Injury 1 66.48 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
CSD could be blocked by the N-methyl-D-aspartate receptor antagonist 2-amino-5-phosphonovaleric acid in all cases.
Negative_regulation (blocked) of CSD associated with depression, antagonist and nmda receptor
1) Confidence 0.36 Published 2001 Journal Brain Res. Section Abstract Doc Link 11430863 Disease Relevance 1.26 Pain Relevance 0.63
They were abolished in 2 out of 4 animals following the intraperitoneal (i.p.) administration of SB-220453 (tonabersat: 10 mg kg(-1), 90 min before stimulus application), a novel anticonvulsant that has recently been reported to inhibit CSD.
Negative_regulation (inhibit) of CSD associated with depression and anticonvulsant
2) Confidence 0.28 Published 2003 Journal Magn Reson Imaging Section Abstract Doc Link 14684218 Disease Relevance 0.33 Pain Relevance 0.58
In preclinical studies, tonabersat markedly reduced CSD and CSD-associated events and inhibited gap-junction communication between neurons and satellite glial cells in the trigeminal ganglion.
Negative_regulation (reduced) of CSD in trigeminal ganglion associated with ganglion cysts, depression and trigeminal ganglion
3) Confidence 0.27 Published 2009 Journal Cephalalgia Section Abstract Doc Link 19723120 Disease Relevance 1.27 Pain Relevance 1.10
In preclinical studies, tonabersat markedly reduced CSD and CSD-associated events and inhibited gap-junction communication between neurons and satellite glial cells in the trigeminal ganglion.
Negative_regulation (reduced) of CSD in trigeminal ganglion associated with ganglion cysts, depression and trigeminal ganglion
4) Confidence 0.27 Published 2009 Journal Cephalalgia Section Abstract Doc Link 19723120 Disease Relevance 1.27 Pain Relevance 1.10
The exact pathophysiological mechanism underlying migraine is not fully understood; however, cortical spreading depression (CSD) is thought to provide the basis for migraine aura and may serve as a trigger of migraine pain.
Negative_regulation (depression) of CSD associated with epilepsy, pain, depression and migraine
5) Confidence 0.23 Published 2009 Journal Cephalalgia Section Abstract Doc Link 19723120 Disease Relevance 1.17 Pain Relevance 1.01
This drug altered neither CSD nor the subsequent characteristic effect of NOS inhibition, i.e. a marked widening of CSD.
Negative_regulation (inhibition) of CSD associated with depression
6) Confidence 0.05 Published 2004 Journal Biochem. Pharmacol. Section Abstract Doc Link 15041479 Disease Relevance 0.92 Pain Relevance 0.50
They suggested that CSD inhibition might be a common mode of action of drugs effective in migraine prevention, which is provocative and thought-provoking for several reasons (see Schoenen 2006 for discussion): (i) there is no clinical evidence that CSD occurs in migraine without aura; (ii) all compounds in Ayata et al’s study were administered in very high doses compared to those used in migraine treatment; (iii) and finally, no genetic mutation able to modify the CSD threshold has been identified in the common forms of migraine.
Negative_regulation (inhibition) of CSD associated with depression and migraine
7) Confidence 0.03 Published 2008 Journal Neuropsychiatric Disease and Treatment Section Body Doc Link PMC2646639 Disease Relevance 1.38 Pain Relevance 1.30
Ayata et al (2006) have found in rat that several prophylactic anti-migraine agents (topiramate, valproate, DL-propranolol, amitriptyline and methysergide) inhibit cortical spreading depression (CSD) after chronic administration.
Negative_regulation (inhibit) of CSD associated with depression, migraine and endep
8) Confidence 0.03 Published 2008 Journal Neuropsychiatric Disease and Treatment Section Body Doc Link PMC2646639 Disease Relevance 1.34 Pain Relevance 1.25

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox